LDC Invests in Panthera Biopartners
August 12, 2025
LDC has made a growth investment in Panthera Biopartners, the UK-based Site Management Organisation (SMO) that recruits patients and runs Phase II/III clinical trials, to support the company’s UK and European expansion and capability build-out. The transaction delivers a partial exit for BGF and Gresham House Ventures (with BGF reinvesting as a minority shareholder); senior debt was provided by TDC and LDC will back the existing management team to scale sites and invest in technology.
- Buyers
- LDC
- Targets
- Panthera Biopartners
- Sellers
- BGF, Gresham House Ventures
- Industry
- Healthcare Services
- Location
- Lancashire, United Kingdom
- Transaction Type
- Growth capital
Explore More
Related Acquisitions
-
Warburg Pincus-Led Investor Group Acquires Controlling Stake in PANTHERx Rare
July 13, 2026
Healthcare Services
Warburg Pincus announced that a Warburg Pincus-led investor group agreed to acquire a controlling interest in PANTHERx Rare, a leading independent rare pharmacy in the United States. The sellers include Nautic Partners, General Atlantic, and The Vistria Group, while Nautic Partners and PANTHERx management are expected to remain significant shareholders.
-
Panthera Biopartners Acquires Óbudai Egészségügyi Centrum Kft (OEC)
April 16, 2026
Healthcare Services
LDC-backed Panthera Biopartners has completed its first international acquisition, buying Hungary-based Óbudai Egészségügyi Centrum Kft (OEC). The acquisition adds four clinical research site locations, including a flagship in Budapest, to strengthen Panthera’s patient recruitment capabilities and expand its pan-European clinical trial site network.
-
LDC Invests in Bullen Healthcare
September 11, 2024
Healthcare Services
LDC, the private equity investor affiliated with Lloyds Banking Group, has invested in Liverpool-based Bullen Healthcare to support the company's growth plans and secure its independence. The investment will back management, led by Paul Bullen, to scale clinical services, product innovation and home-delivery capabilities across the UK; Muzinich & Co provided debt financing and several advisers supported the deal.
-
LDC Invests £18m Minority Stake in TMC Pharma Services
August 24, 2022
Healthcare Services
LDC has made an £18m minority growth investment in TMC Pharma Services to back the company’s international expansion and capability build-out. The capital will support TMC’s plans to expand into the US and Asia, double its number of full-time employees over the next five years and open new offices in key markets.
-
LDC Makes Minority Growth Investment in PAM
June 28, 2021
Healthcare Services
LDC has completed a minority growth investment in PAM, a Warrington-headquartered preventative occupational health and wellbeing provider, to support the management team’s organic growth plans and new product launches such as telemedicine and digital CBT services. The deal will see LDC advisors join the board alongside founder and CEO James Murphy, and Andy Parker appointed as Non-Executive Chairman to support the company’s expansion.
-
LDC Invests £13m in Hybrid
June 21, 2021
Marketing & Advertising
LDC, the private equity arm of Lloyds Banking Group, has invested £13 million in Bristol-based digital media and marketing agency Hybrid to support organic growth and enable targeted acquisitions. Hybrid, which serves higher education institutions and global technology brands and employs more than 70 people across offices in Bristol, Kuala Lumpur and Sydney, will retain its management team while founder James Craven remains as a Board Director.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.